Other languages Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Real-time Estimate Cboe BZX Other stock markets 10:38:47 2024-05-23 am EDT			5-day change	1st Jan Change
12.28 ^USD	-3.27%		-16.61%	-43.99%

May. 16	Transcript : Viridian Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 04:35 PM
May. 09	Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Viridian Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Viridian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Viridian Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer	Feb. 16
Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer	Feb. 16
Viridian Therapeutics Prices Common Stock Offering at $21 per Share	Jan. 18
Viridian Therapeutics Starts Underwritten Stock Offering; Shares Fall After Hours	Jan. 17
Viridian Therapeutics, Inc. Provides Key Updates on its Anti-Insulin-Like Growth Factor 1 Receptor (IGF-1R) Programs in Thyroid Eye Disease and its Programs Targeting FcRn	Jan. 08
Viridian Therapeutics, Inc. Announces Executive Changes	Jan. 08
Viridian Therapeutics Q3 Loss Widens, Revenue Drops	Nov. 13
Viridian Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors	Nov. 02
Viridian Therapeutics Names Stephen Mahoney Chief Executive	23-10-30
Viridian Therapeutics, Inc. Appoints Thomas Beetham as Chief Operating Officer	23-10-30
Viridian Therapeutics, Inc. Announces Management Changes	23-10-30
Viridian Therapeutics, Inc. Appoints Stephen Mahoney as Chief Executive Officer	23-10-30
Ypsomed to Customize, Supply Autoinjector Pen Device for Viridian Therapeutics	23-10-26
Ypsomed geht Partnerschaft mit Viridian Therapeutics ein	23-10-26
Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors	23-09-25
Viridian Therapeutics, Inc. Announces Executive Changes	23-09-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Other languages

Filters